Suboptimal lopinavir exposure in infants on rifampicin treatment receiving double-dosed or semi-superboosted lopinavir/ritonavir: time for a change.

Tom G JacobsV MumbiroM ChitsamatangaN NamuziyaA PassanducaS Domínguez-RodríguezA TagarroK J NathooB NdunaA BallesterosL MadridH A MujuruC ChabalaW C BuckP RojoD M BurgerC MoraledaA Colbersnull null

Published in: Journal of acquired immune deficiency syndromes (1999) (2023)

Double-dosed or semi-superboosted LPV/r for infants aged 1-12 months receiving rifampicin resulted in substantial proportions of subtherapeutic LPV levels. There is an urgent need for data on alternative antiretroviral regimens in infants with HIV/TB co-infection, including twice-daily dolutegravir.

Keyphrases

antiretroviral therapy
hiv infected
mycobacterium tuberculosis
hiv positive
human immunodeficiency virus
hiv infected patients
hiv aids
pulmonary tuberculosis
physical activity
big data
south africa
deep learning
artificial intelligence